by John Conrad | Jun 10, 2024 | NewsBrief
In a significant development for patients with vanishing white matter (VWM) disease, AbbVie and Alphabet’s Calico announced on Friday that their investigational eIF2B activator, fosigotifator, has been selected to participate in the FDA’s new Support for...
by John Conrad | Jun 10, 2024 | NewsBrief
In a time of economic uncertainty and inflation, the STEM job market remains resilient. Despite the wave of layoffs in the tech sector in 2023 and 2024, the demand for STEM and R&D talent in the U.S. remains strong overall. A recent analysis of over 5,000 job...
by John Conrad | Jun 7, 2024 | NewsBrief
AbbVie’s strategic acquisition of ImmunoGen for $10.1 billion in November 2023 is already showing promising results. The deal, which included the antibody-drug conjugate (ADC) Elahere, has yielded positive outcomes in a recent Phase 2 study. According to...
by John Conrad | Jun 7, 2024 | NewsBrief
Illinois has long been recognized as a center of innovation and growth, particularly in the bio manufacturing industry. The state’s commitment to fostering a supportive business environment, coupled with its highly skilled workforce and world-class research...
by John Conrad | Jun 6, 2024 | NewsBrief
The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion...
by John Conrad | Jun 5, 2024 | NewsBrief
Abbott Laboratories has received clearance from the U.S. Food and Drug Administration (FDA) to sell its Lingo glucose monitor over the counter, without a prescription. The clearance, which came on May 29 according to the FDA’s website, positions Abbott to...
